Rate My Professor Julie Redfern

Redfern's research specializes in preventive cardiology, cardiac rehabilitation, secondary prevention of cardiovascular disease, and digital health innovations, particularly mobile phone text messaging interventions. She led the landmark TEXT ME randomized controlled trial, published in JAMA (2015), which demonstrated significant risk factor improvements in coronary heart disease patients through lifestyle-focused text messaging. With over 400 peer-reviewed publications cited more than 11,000 times, key works include the Cochrane review on text messaging for medication adherence (2024) and contributions to national CVD policy recommendations (2023). Her impact is evidenced by major NHMRC funding, including a $2.87 million Investigator Grant Leadership 2—the highest ranked in Health Services. Awards include the 2022 NSW Woman of Excellence, Fellowship of the Australian Academy of Health and Medical Sciences (2023), European Society of Cardiology Fellowship (2022), University of Sydney Vice-Chancellor’s Award for Leadership and Mentoring (2021), and numerous trial and publication accolades. She has supervised multiple PhD students to completion and holds leadership roles such as Chair of the Australian Cardiovascular Alliance Scientific Advisory Committee.